{"organizations": [], "uuid": "e9a895f8d4a8991754dd5d5ffa767b811d982a44", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nicox-provides-2018-outlook-and-20/brief-nicox-provides-2018-outlook-and-2017-estimated-financial-results-idUSFWN1QO03H", "country": "US", "domain_rank": 408, "title": "BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-06T14:47:00.000+02:00", "replies_count": 0, "uuid": "e9a895f8d4a8991754dd5d5ffa767b811d982a44"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nicox-provides-2018-outlook-and-20/brief-nicox-provides-2018-outlook-and-2017-estimated-financial-results-idUSFWN1QO03H", "ord_in_thread": 0, "title": "BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results", "locations": [], "entities": {"persons": [{"name": "nicox", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "etm", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - NICOX SA:\n* PROVIDES 2018 OUTLOOK AND 2017 ESTIMATED FINANCIAL RESULTS\n* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON\n* PIPELINE CANDIDATES MOVING TOWARDS CLINICAL DEVELOPMENT, WITH IND SUBMISSIONS TO THE U.S. FDA PLANNED FOR NCX 470 IN Q3 2018 AND NCX 4251 IN Q1 2019\n* ESTIMATED CASH POSITION OF â‚¬41.4 MILLION AS OF DECEMBER 31, 2017\n* IN 2018 WE ALSO EXPECT TO MAKE SIGNIFICANT ADVANCES IN OUR NO-DONATING RESEARCH PIPELINE - CEO Source text for Eikon: Further company coverage: (Gdynia Newsroom:)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T14:47:00.000+02:00", "crawled": "2018-03-07T19:21:16.000+02:00", "highlightTitle": ""}